Summit Therapeutics Inc.
SMMT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $704 | $1,809 |
| % Growth | – | -100% | -61.1% | – |
| Cost of Goods Sold | $15,007 | $2,050 | $2,514 | $0 |
| Gross Profit | -$15,007 | -$2,050 | -$1,810 | $1,809 |
| % Margin | – | – | -257% | 100% |
| R&D Expenses | $150,777 | $59,471 | $51,999 | $85,352 |
| G&A Expenses | $60,527 | $23,741 | $26,700 | $23,611 |
| SG&A Expenses | $60,527 | $30,265 | $26,700 | $23,611 |
| Sales & Mktg Exp. | $0 | -$2,050 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$5,948 | -$20,968 |
| Operating Expenses | $211,304 | $87,686 | $64,283 | $87,995 |
| Operating Income | $313 | -$89,736 | -$59,633 | -$86,186 |
| % Margin | – | – | -8,467% | -4,764.3% |
| Other Income/Exp. Net | -$221,628 | -$526,138 | -$6,693 | -$2,416 |
| Pre-Tax Income | -$221,315 | -$615,874 | -$78,782 | -$88,602 |
| Tax Expense | $0 | -$946 | $0 | $0 |
| Net Income | -$221,315 | -$614,928 | -$78,782 | -$88,602 |
| % Margin | – | – | -11,185.9% | -4,897.8% |
| EPS | -0.31 | -0.99 | -0.41 | -0.96 |
| % Growth | 68.7% | -141.5% | 57.3% | – |
| EPS Diluted | -0.31 | -0.99 | -0.38 | -0.96 |
| Weighted Avg Shares Out | 718,542 | 619,646 | 193,336 | 92,239 |
| Weighted Avg Shares Out Dil | 718,542 | 619,646 | 193,336 | 92,239 |
| Supplemental Information | – | – | – | – |
| Interest Income | $13,466 | $10,403 | $1,513 | $179 |
| Interest Expense | $8,686 | $16,461 | $4,401 | $281 |
| Depreciation & Amortization | $17,148 | $155 | $1,263 | $2,455 |
| EBITDA | -$212,853 | -$69,451 | -$73,118 | -$85,905 |
| % Margin | – | – | -10,381.7% | -4,748.8% |